Gates Capital Management Inc. Buys 4,698 Shares of DaVita Inc. $DVA

Key Points

• Gates Capital Management Inc. increased its holdings in DaVita Inc. by 0.7% in Q1, now owning 722,205 shares worth approximately $110.5 million.
• Wall Street analysts have upgraded DaVita's rating from "hold" to "buy," with a consensus target price of $164.00.
• DaVita reported $2.95 earnings per share for the last quarter, surpassing estimates and showing a revenue increase of 6.1% year-over-year.

Gates Capital Management Inc. increased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 0.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 722,205 shares of the company's stock after purchasing an additional 4,698 shares during the period. DaVita makes up 2.2% of Gates Capital Management Inc.'s portfolio, making the stock its 14th biggest position. Gates Capital Management Inc. owned approximately 0.94% of DaVita worth $110,476,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. UMB Bank n.a. lifted its stake in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Copia Wealth Management bought a new stake in shares of DaVita during the 4th quarter worth approximately $30,000. National Pension Service raised its stake in shares of DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after purchasing an additional 84 shares in the last quarter. Y.D. More Investments Ltd bought a new stake in shares of DaVita during the 1st quarter worth approximately $35,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in shares of DaVita during the 1st quarter worth approximately $83,000. Institutional investors own 90.12% of the company's stock.

DaVita Stock Performance

NYSE DVA traded down $1.12 on Wednesday, reaching $135.83. The stock had a trading volume of 583,942 shares, compared to its average volume of 851,361. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The firm has a fifty day moving average of $139.68 and a two-hundred day moving average of $142.25. DaVita Inc. has a 1-year low of $126.07 and a 1-year high of $179.60. The company has a market cap of $9.71 billion, a P/E ratio of 13.36, a price-to-earnings-growth ratio of 0.99 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company's revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Insider Buying and Selling

In other news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Barclays dropped their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, August 22nd. Finally, Truist Financial set a $148.00 target price on DaVita in a report on Friday, August 8th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, DaVita currently has a consensus rating of "Hold" and a consensus target price of $164.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.